- Home
- ARDX
ARDX
Ardelyx Inc.
as of 12-05-2025 4:00pm EST
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 1.4B | IPO Year: | 2014 |
| Target Price: | $10.65 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.21 - $6.78 | Next Earning Date: | 10-30-2025 |
| Revenue: | $398,234,000 | Revenue Growth: | 58.12% |
| Revenue Growth (this year): | 22.71% | Revenue Growth (next year): | 27.81% |
AI-Powered ARDX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
President & CEO
Avg Cost/Share
$5.54
Shares
46,887
Total Value
$259,608.63
Owned After
1,455,363
SEC Form 4
Chief Patient Officer
Avg Cost/Share
$5.54
Shares
6,426
Total Value
$35,580.12
Owned After
359,896
SEC Form 4
See Remarks
Avg Cost/Share
$5.54
Shares
5,560
Total Value
$30,785.16
Owned After
271,181
SEC Form 4
See Remarks
Avg Cost/Share
$5.54
Shares
5,995
Total Value
$33,193.72
Owned After
299,895
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$5.54
Shares
5,814
Total Value
$32,191.54
Owned After
295,684
SEC Form 4
See Remarks
Avg Cost/Share
$5.54
Shares
11,086
Total Value
$61,382.07
Owned After
108,914
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | ARDX | President & CEO | Nov 21, 2025 | Sell | $5.54 | 46,887 | $259,608.63 | 1,455,363 | |
| Williams Laura A | ARDX | Chief Patient Officer | Nov 21, 2025 | Sell | $5.54 | 6,426 | $35,580.12 | 359,896 | |
| Kelliher Mike | ARDX | See Remarks | Nov 21, 2025 | Sell | $5.54 | 5,560 | $30,785.16 | 271,181 | |
| GRAMMER ELIZABETH A | ARDX | See Remarks | Nov 21, 2025 | Sell | $5.54 | 5,995 | $33,193.72 | 299,895 | |
| Foster Eric Duane | ARDX | Chief Commercial Officer | Nov 21, 2025 | Sell | $5.54 | 5,814 | $32,191.54 | 295,684 | |
| Reilly Joseph James | ARDX | See Remarks | Nov 21, 2025 | Sell | $5.54 | 11,086 | $61,382.07 | 108,914 |
Compare ARDX vs Leading Stocks
See how ARDX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.